Sean Mc Allister
About Sean Mc Allister
Sean McAllister serves as the Director of Pharmacology at CytomX Therapeutics, where he focuses on pharmacogenomic precision medicine oncology. He has authored over 35 publications and holds 4 patents, with expertise in drug screening and molecular biology techniques.
Work at CytomX Therapeutics
Sean Mc Allister serves as the Director of Pharmacology at CytomX Therapeutics, a position he has held since 2021. In this role, he focuses on advancing pharmacological research and development. His responsibilities include managing a team of up to five employees who specialize in in vitro assays, in vivo model development, and pharmacokinetic studies. Mc Allister has contributed to the development and validation of patient-derived xenograft tumor and PDX culture models across various cancer types, enhancing the company's capabilities in precision oncology.
Education and Expertise
Sean Mc Allister earned his PhD in Pharmacology and Toxicology from the Medical College of Virginia Commonwealth University. His academic background provides a strong foundation for his work in pharmacology, particularly in high-throughput drug screen development and molecular biology techniques for gene function discovery. This expertise supports his involvement in innovative projects aimed at improving cancer treatment outcomes.
Background
Sean Mc Allister has a robust background in pharmacology, with a strong track record of scientific accomplishments, including over 35 publications and four patents. His research interests are primarily focused on pharmacogenomic precision medicine oncology, which aims to tailor cancer treatments based on individual genetic profiles. He has been actively involved in the Cancer Avatar Project, which aligns with this focus.
Achievements
Throughout his career, Sean Mc Allister has led significant projects related to cannabinoid-based inhibitors and novel drug combinations targeting immune checkpoint inhibitor resistance in melanoma. He has collaborated with major pharmaceutical companies and academic institutions, including GW Pharmaceuticals, Pfizer, AstraZeneca, and Amgen. His work has contributed to advancements in cancer research and therapeutic strategies.
Research and Development Initiatives
Sean Mc Allister has extensive experience in developing syngeneic mouse tumor models that study primary and metastatic tumor progression, as well as immune checkpoint inhibitor-resistant models of cancer. His research initiatives aim to enhance understanding of cancer biology and improve therapeutic approaches, contributing to the field of oncology.